(PBH) Prestige Brand Holdings - Overview
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NYSE (USA) | Market Cap: 2.235m USD | Total Return: -46.1% in 12m
OTC Medicines, Eye Care, Feminine Hygiene, Oral Care, Skin Treatments
Total Rating 33
Safety 70
Buy Signal -0.83
Drug Manufacturers - Specialty & Generic
Industry Rotation: -0.5
Industry Rotation: -0.5
Market Cap:
2.24B
Avg Turnover: 38.1M
Avg Turnover: 38.1M
Risk 3d forecast
Volatility28.4%
VaR 5th Pctl4.98%
VaR vs Median6.64%
Reward TTM
Sharpe Ratio-2.13
Rel. Str. IBD3.6
Rel. Str. Peer Group5.8
Character TTM
Beta0.367
Beta Downside0.688
Hurst Exponent0.541
Drawdowns 3y
Max DD48.45%
CAGR/Max DD-0.15
CAGR/Mean DD-0.55
EPS (Earnings per Share)
EPS CAGR: 3.27%
EPS Trend: 26.8%
EPS Trend: 26.8%
Last SUE: -2.07
Qual. Beats: -1
Qual. Beats: -1
Revenue
Rev. CAGR: 0.44%
Rev. Trend: -14.9%
Rev. Trend: -14.9%
Last SUE: -1.28
Qual. Beats: -1
Qual. Beats: -1
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Description: PBH Prestige Brand Holdings
Prestige Consumer Healthcare Inc. (PBH) specializes in the development, marketing, and distribution of over-the-counter (OTC) health and personal care products. The company manages a portfolio of established brands across categories such as pediatrics, eye care, women’s health, and gastrointestinal relief. Key brands include Monistat, Clear Eyes, Dramamine, and Fleet. Prestige operates primarily through two segments: North American OTC Healthcare and International OTC Healthcare.
The company utilizes an asset-light business model, often outsourcing manufacturing to third-party providers to maintain focus on brand management and retail distribution. The OTC sector is characterized by high consumer loyalty and stable demand, as many products address non-discretionary health needs. PBH distributes its products through diverse channels, including mass merchandisers, drug stores, and e-commerce platforms.
Investors may find it useful to examine ValueRay for deeper insights into the company’s valuation metrics.
- Strategic brand acquisitions drive inorganic revenue growth and market share expansion
- Consumer health spending patterns influence core North American OTC segment revenue
- Supply chain efficiency and raw material costs impact consolidated gross margins
- E-commerce channel penetration accelerates sales growth within the International OTC segment
- High leverage levels make interest rate fluctuations a key earnings variable
Piotroski VR‑10 (Strict)
6.5
| Net Income: 190.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 0.02 > 1.0 |
| NWC/Revenue: 28.53% < 20% (prev 30.03%; Δ -1.51% < -1%) |
| CFO/TA 0.07 > 3% & CFO 265.4m > Net Income 190.3m |
| Net Debt (981.6m) to EBITDA (330.4m): 2.97 < 3 |
| Current Ratio: 3.57 > 1.5 & < 3 |
| Outstanding Shares: last quarter (47.7m) vs 12m ago -4.78% < -2% |
| Gross Margin: 53.96% > 18% (prev 0.56%; Δ 5.34k% > 0.5%) |
| Asset Turnover: 31.33% > 50% (prev 33.44%; Δ -2.11% > 0%) |
| Interest Coverage Ratio: 7.07 > 6 (EBITDA TTM 330.4m / Interest Expense TTM 42.3m) |
Altman Z''
3.84
| A: 0.09 (Total Current Assets 431.5m - Total Current Liabilities 120.9m) / Total Assets 3.55b |
| B: 0.49 (Retained Earnings 1.75b / Total Assets 3.55b) |
| C: 0.09 (EBIT TTM 299.1m / Avg Total Assets 3.47b) |
| D: 1.04 (Book Value of Equity 1.72b / Total Liabilities 1.66b) |
| Altman-Z'' Score: 3.84 = AA |
Beneish M
-3.01
| DSRI: 1.03 (Receivables 191.9m/194.3m, Revenue 1.09b/1.14b) |
| GMI: 1.04 (GM 53.96% / 56.27%) |
| AQI: 1.00 (AQ_t 0.83 / AQ_t-1 0.83) |
| SGI: 0.96 (Revenue 1.09b / 1.14b) |
| TATA: -0.02 (NI 190.3m - CFO 265.4m) / TA 3.55b) |
| Beneish M-Score: -3.01 (Cap -4..+1) = AA |
What is the price of PBH shares?
As of May 21, 2026, the stock is trading at USD 47.19 with a total of 483,504 shares traded.
Over the past week, the price has changed by -8.92%, over one month by -19.58%, over three months by -32.18% and over the past year by -46.11%.
Over the past week, the price has changed by -8.92%, over one month by -19.58%, over three months by -32.18% and over the past year by -46.11%.
Is PBH a buy, sell or hold?
Prestige Brand Holdings has received a consensus analysts rating of 3.71.
Therefor, it is recommend to hold PBH.
- StrongBuy: 3
- Buy: 0
- Hold: 3
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the PBH price?
| Analysts Target Price | 66.8 | 41.6% |
Prestige Brand Holdings (PBH) - Fundamental Data Overview
as of 21 May 2026
P/E Trailing = 12.0691 P/E Forward = 10.3413
P/S = 2.0534
P/B = 1.1655
P/EG = 1.6682
Revenue TTM = 1.09b USD
EBIT TTM = 299.1m USD
EBITDA TTM = 330.4m USD
Long Term Debt = 994.0m USD (from longTermDebt, last quarter)
Short Term Debt = 12.6m USD (from shortTermDebt, last quarter)
Debt = 1.05b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 981.6m USD (from netDebt column, last quarter)
Enterprise Value = 3.22b USD (2.24b + Debt 1.05b - CCE 63.9m)
Interest Coverage Ratio = 7.07 (Ebit TTM 299.1m / Interest Expense TTM 42.3m)
EV/FCF = 12.65x (Enterprise Value 3.22b / FCF TTM 254.2m)
FCF Yield = 7.90% (FCF TTM 254.2m / Enterprise Value 3.22b)
FCF Margin = 23.35% (FCF TTM 254.2m / Revenue TTM 1.09b)
Net Margin = 17.48% (Net Income TTM 190.3m / Revenue TTM 1.09b)
Gross Margin = 53.96% ((Revenue TTM 1.09b - Cost of Revenue TTM 501.3m) / Revenue TTM)
Gross Margin QoQ = 50.02% (prev 55.52%)
Tobins Q-Ratio = 0.91 (Enterprise Value 3.22b / Total Assets 3.55b)
Interest Expense / Debt = 1.09% (Interest Expense 11.4m / Debt 1.05b)
Taxrate = 16.74% (10.8m / 64.8m)
NOPAT = 249.0m (EBIT 299.1m * (1 - 16.74%))
Current Ratio = 3.57 (Total Current Assets 431.5m / Total Current Liabilities 120.9m)
Debt / Equity = 0.55 (Debt 1.05b / totalStockholderEquity, last quarter 1.89b)
Debt / EBITDA = 2.97 (Net Debt 981.6m / EBITDA 330.4m)
Debt / FCF = 3.86 (Net Debt 981.6m / FCF TTM 254.2m)
Total Stockholder Equity = 1.85b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.48% (Net Income 190.3m / Total Assets 3.55b)
RoE = 10.29% (Net Income TTM 190.3m / Total Stockholder Equity 1.85b)
RoCE = 10.52% (EBIT 299.1m / Capital Employed (Equity 1.85b + L.T.Debt 994.0m))
RoIC = 8.73% (NOPAT 249.0m / Invested Capital 2.85b)
WACC = 5.24% (E(2.24b)/V(3.28b) * Re(7.27%) + D(1.05b)/V(3.28b) * Rd(1.09%) * (1-Tc(0.17)))
Discount Rate = 7.27% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares (quarterly) Correlation: -82.22 | Cagr: -2.19%
[DCF] Terminal Value 86.84% ; FCFF base≈249.9m ; Y1≈263.2m ; Y5≈310.0m
[DCF] Fair Price = 172.6 (EV 9.16b - Net Debt 981.6m = Equity 8.18b / Shares 47.4m; r=6.0% [WACC]; 5y FCF grow 5.83% → 3.0% )
EPS Correlation: 26.76 | EPS CAGR: 3.27% | SUE: -2.07 | # QB: -1
Revenue Correlation: -14.88 | Revenue CAGR: 0.44% | SUE: -1.28 | # QB: -1
EPS current Quarter (2026-06-30): EPS=0.87 | Chg30d=-12.12% | Revisions=-33% | Analysts=5
EPS next Quarter (2026-09-30): EPS=1.20 | Chg30d=+4.60% | Revisions=-33% | Analysts=2
EPS current Year (2027-03-31): EPS=4.61 | Chg30d=-4.13% | Revisions=-60% | GrowthEPS=+5.2% | GrowthRev=+16.1%
EPS next Year (2028-03-31): EPS=5.07 | Chg30d=+0.53% | Revisions=-56% | GrowthEPS=+10.1% | GrowthRev=+9.5%
[Analyst] Revisions Ratio: -60%